Recently Added |View More
Roswell Park Earns ‘Exceptional’ Rating from National Cancer Institute With Best-Ever Core Grant
Region’s only Comprehensive Cancer Center earns maximum rating, marking five decades of consecutive NCI support.
First-in-Human Clinical Trial for B-cell Lymphoma Using “Armored” CAR T Cells Opens at Roswell Park
Chimeric antigen receptor (CAR) T-cell therapy is emerging as an effective therapeutic strategy for patients with B-cell lymphoid cancers.
A Comprehensive Overview of Tumor-Infiltrating Lymphocyte (TIL) Therapy for Metastatic Melanoma
Tuesday, April 9, 2024 5:30 - 6:30 PM EDT - On the heels of the FDA’s recent approval of AMTAGVI (lifileucel) for unrescectable or metastatic melanoma, join Roswell Park subject matter experts for a comprehensive provider education event.
For Roswell Park’s Cell Therapy Team, Innovation is the Norm
Roswell Park Comprehensive Cancer Center is dedicated to becoming the leading cellular therapy innovation engine in the United States, if not the world, in the next 10 years.
Meet the Team: Shernan Holtan, MD
The newest member of the cellular therapy research team and Chief of the Bone Marrow and Transplantation Service at Roswell Park Comprehensive Cancer Center is eager to continue advancing the field.
Amtagvi, First FDA-Approved Cell Therapy for Solid-Tumor Cancers, Available at Roswell Park
Expanding access to a breakthrough treatment option for patients with metastatic melanoma, Roswell Park Comprehensive Cancer Center has been approved to administer the newly FDA-approved tumor-infiltrating lymphocyte (TIL) therapy Amtagvi.
This site is intended for healthcare professionals